Presented at 8th Congress of Pharmacy in North Macedonia, Ohrid, 1–4 October 2026 · All posters from this congress
Pharmaceutical IndustryOpen accessPoster communication · 2026-0062

Evaluation of carry-over, product quality and cleaning validation following a batch campaign manufacturing of benzydamine hydrochloride spray 0.15%

Elena Petrovska Kostadinoska1✉, Irena Slaveska Spirevska1, Katerina Kochova1, Kristina Grncaroska1, Silvana Janevikj1, Jana Micevska1, Milena Prculovska1

  1. 1 Replek Farm, Skopje, Str. Kozle 188 Skopje, Republic of North Macedonia

Received 3 November 2026 · Accepted 14 November 2026 · Published 14 November 2026

Article PDF · Original poster (PDF)

view
1
download
1
countries
2

Since publication · journal site · robots excluded

Key messages

  1. Campaign manufacturing of benzydamine HCl spray 0.15% without intermediate cleaning is feasible and safe for up to 10 consecutive batches.
  2. Residue levels remained below the calculated MACO with no cumulative build-up across the campaign.
  3. Post-campaign CIP cleaning validation confirmed full restoration of a validated clean state, supporting a 10-batch campaign strategy.

Abstract

Introduction

Campaign manufacturing reduces equipment downtime, water and cleaning-agent use, and production cost but must be scientifically justified to protect product quality and patient safety under EU GMP. Consecutive same-product batches remove cross-contamination risk between different APIs, yet residue build-up, degradation in poorly drained areas, and microbial proliferation remain relevant quality risks. Benzydamine hydrochloride is a topical NSAID with analgesic and anti-inflammatory action, used for inflammatory conditions of the oral cavity and pharynx.

Materials and methods

Ten consecutive commercial-scale batches were produced using the same equipment and approved manufacturing process without intermediate cleaning or sanitization, only standardized drain-down and line-clearance after every batch. A full automated CIP cycle was executed only after completion of batch 10. Risk-based swab sampling targeted highest residue-retention potential locations. Validated, stability-indicating RP-HPLC with UV detection at 232 nm was used for analysis. MACO derivation was based on toxicology data applying LOEL/LOAEL approach and PDE calculations.

Results

Method validation showed high specificity, linearity, and precision suitable for monitoring trace-level benzydamine residues. Residue levels stayed below the calculated MACO with no cumulative build-up across the campaign. Standardized drain-down and line-clearance were effective after each batch. Full CIP cycle was only needed after batch 10, followed by cleaning validation swabbing confirming restoration of a validated clean state.

Conclusion

Ten consecutive batches of benzydamine HCl spray 0.15% can be manufactured without intermediate cleaning while maintaining product quality, microbiological control and GMP compliance. Residues stayed below MACO with no cumulative build-up. Post-campaign CIP cleaning validation confirmed full restoration of a validated clean state. Findings provide scientific justification for a 10-batch campaign manufacturing strategy.

Original poster

References

  1. European Commission, 2015. EudraLex – Volume 4: EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use, Annex 15: Qualification and Validation.; European Medicine Agency (EMA), 2014. Guideline on setting health-based exposure limits for use in risk identification in the manufacture of different medicinal products in healthcare facilities, EMA/CHMP/CVMP/SWP/169430/2012.; National Center for Biotechnology Information, 2026. PubChem Compound summary for CID 65464, Benzydamine hydrochloride. Retrieved: June 10, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/Benzydamine-Hydrochloride; Tox by design, 2024. PDE Monograph for Benzydamine Hydrochloride, Oromucosal route, October, Division of Socosur Chem, 54 Rue de Londres, Paris France.
Keywords
Benzydamine hydrochloride · campaign manufacturing · carry-over · cleaning validation · product quality
Received
3 November 2026
Accepted
14 November 2026
Published
14 November 2026
Peer review
Single-anonymized review by the Editorial Board · How we review
License
© The Authors 2026. Distributed under CC BY 4.0
Journal
MP Journal of Medical Research · ISSN 3144-8402

Related posters